Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) announces that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world’s leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencast’s strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
Read the full article: Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint //
Source: https://ir.waldencast.com/node/9021/pdf